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The effects of hormone status and age on the development of tolerance to 9 -THC
were assessed in sham-operated (intact) or ovariectomized (OVX) female rats that
received either intraperitoneal saline or 5.6 mg/kg of 9 -THC daily from postnatal day
(PD) 75–180 (early adulthood onward) or PD 35–140 (adolescence onward). During
this time, the four groups for each age (i.e., intact/saline, intact/THC, OVX/saline, and
OVX/THC) were trained in a learning and performance procedure and dose-effect curves
were established for 9 -THC (0.56–56 mg/kg) and the cannabinoid type-1 receptor
(CB1R) antagonist rimonabant (0.32–10 mg/kg). Despite the persistence of small rate-
decreasing and error-increasing effects in intact and OVX females from both ages
during chronic 9 -THC, all of the 9 -THC groups developed tolerance. However, the
magnitude of tolerance, as well as the effect of hormone status, varied with the age at
which chronic 9 -THC was initiated. There was no evidence of dependence in any of
the groups. Hippocampal protein expression of CB1R, AHA1 (a co-chaperone of CB1R)
and HSP90β (a molecular chaperone modulated by AHA-1) was affected more by OVX
than chronic 9 -THC; striatal protein expression was not consistently affected by either
manipulation. Hippocampal brain-derived neurotrophic factor expression varied with
age, hormone status, and chronic treatment. Thus, hormonal status differentially affects
the development of tolerance to the disruptive effects of delta-9-tetrahydrocannabinol
( 9 -THC) on learning and performance behavior in adolescent, but not adult, female
rats. These factors and their interactions also differentially affect cannabinoid signaling
proteins in the hippocampus and striatum, and ultimately, neural plasticity.
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Introduction
Research over the past decade or so has highlighted the fact that the cannabinoids can produce
sexually dimorphic eﬀects on learning and memory, as well as on a variety of behavioral
processes and physiological systems. These sexually dimorphic eﬀects most likely have their
origin during adolescence when the sex hormones begin to exert their organizational and
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activational eﬀects (Arnold and Breedlove, 1985; Sisk and
Zehr, 2005). Thus, any disruption of these organizational and
activational eﬀects, such as a reduction of the sex hormones
or excessive exogenous activation of speciﬁc neurotransmitter
systems, could produce long-term disruptions of the systems or
behaviors mediated by those hormones. This may be especially
true for the cannabinoid system, as there is a growing literature
on this system’s age-dependent, bidirectional interaction with the
sex hormones, particularly in females (Gorzalka and Dang, 2012).
For example, we have found that estradiol capsules implanted
in ovariectomized (OVX) females signiﬁcantly attenuated both
the rate-decreasing and error-increasing eﬀects of 9-THC in
mature females responding in an operant task where subjects
learned (acquired) a diﬀerent sequence of responses each session
(Daniel et al., 2002). However, this eﬀect of estradiol was later
shown to be age-dependent, as intact females were found to be
more sensitive than OVX females to the disruptions of rate and
accuracy produced by 40 days of chronic9-THC administration
during adolescence (Winsauer et al., 2011a). The increased
sensitivity of intact females compared to OVX females was also
evident when 40 days of chronic 9-THC administration was
initiated during early adulthood (Winsauer and Sutton, 2014) –
suggesting that estradiol may not be ‘protective’ until long after
its organizational and activational eﬀects have been established.
The purpose of the present study was to determine whether
the initiation of chronic 9-THC administration during either
adolescence or early adulthood would aﬀect the development
of tolerance to its disruptive eﬀects on the operant procedure
of learning (acquisition) and performance behavior that was
used in the aforementioned studies. In this procedure, subjects
both acquire a new sequence of responses each session (i.e.,
repeated acquisition) and emit a well-rehearsed sequence of
responses (performance). Such baselines of operant behavior
have several advantages. One advantage is that responding in the
performance component can serve as a behavioral control for the
non-speciﬁc eﬀects of either drug or hormone status. Another
advantage is that having a stable baseline of repeated acquisition
behavior avoids the confound associated with “learning to learn”
(Harlow, 1949), and allows for the assessment of learning
over a long period of time. The major diﬀerence, however,
between the present study and previous studies was that there
was no drug-free period after chronic 9-THC was initiated,
which for the adolescents resulted in almost life-long 9-THC
administration.
Few human or animal studies have taken this type of
longitudinal approach, or administered chronic 9-THC for this
duration (e.g., Fehr et al., 1976; Ali et al., 1989; Winsauer et al.,
2011b). Most of the prospective human studies are those that
have followed self-reported users over long periods of time and
then tested them periodically (Brook et al., 2008; Meier et al.,
2012) or examined the acute eﬀects of 9-THC in frequent or
long-time users as compared to non-users (Solowij et al., 1991;
Kirk and de, 1999; Pope et al., 2003; Jacobsen et al., 2004;
Kanayama et al., 2004; Lane et al., 2007). Brook et al. (2008), for
example, followed 749 participants over a period of 13 years and
chronicled any emergent health problems by interviewing them
at mean ages of 14, 16, 22, and 27 years. Of note, marijuana
use was signiﬁcantly associated with respiratory problems,
general malaise, neurocognitive problems, and lower academic
achievement and functioning. Similar ﬁndings were also obtained
from the Dunedin study, a prospective study of 1,037 individuals
followed from birth to age 38. Interviews for this study occurred
at 18, 21, 26, 32, and 38 years of age, and neuropsychological
testing was conducted at age 13 (Meier et al., 2012). Although
there were concerns that not enough weight was given to the
importance of socioeconomic status in this study (cf. Rogeberg,
2013), the results indicated that there may be residual eﬀects as
‘cessation of cannabis use did not fully restore neuropsychological
functioning among those that started during adolescence.’
Foremost among the ﬁndings from longitudinal studies such
as the Dunedin study are that executive functioning (Meier
et al., 2012) and processing speed or reaction time (Mendhiratta
et al., 1988; Wilson et al., 1994; Hunault et al., 2009) tend to
be the most susceptible to the long-term marijuana use and
that disruptions of these neurocognitive processes can eventually
lead to motivational and academic diﬃculties (for reviews,
see Lynskey and Hall, 2000; Gruber and Pope, 2002; Volkow
et al., 2014). These ﬁndings have also been bolstered by the
human studies examining the acute and chronic eﬀects of 9-
THC, which have documented 9-THC-induced disruptions in
a number of domains of neuropsychological functioning. In
an often cited paper, Ehrenreich et al. (1999) found impaired
reaction time for a visual scanning task, but no eﬀect on several
other attentional functions. Pope et al. (2003) found that there
was a marked diﬀerence in verbal intelligence quotient between
early onset users and late-onset users. Deﬁcits in working
memory have also featured prominently in the eﬀects reported
by a number of investigators (Wilson et al., 1994; Jacobsen et al.,
2004; Kanayama et al., 2004; Hunault et al., 2009).
Another important aspect of the present study was the
assessment of the long-term eﬀects of 9-THC administration
on cannabinoid signaling in the hippocampus and striatum.
These two brain regions were found by us (Winsauer et al., 2011a)
and others (Breivogel et al., 1999; Rubino et al., 2000a; McKinney
et al., 2008; Burston et al., 2010; Hirvonen et al., 2012) to be
directly aﬀected by long-term chronic 9-THC administration
during adolescence and to be regions where there was clear
evidence of an interaction between cannabinoid administration
and ovarian hormones. In our study, a period of chronic 9-
THC during adolescence increased cannabinoid type-1 receptors
(CB1Rs) in the hippocampus of intact female rats, and had
no eﬀect on CB1R in striatum, although OVX reduced CB1R
irrespective of chronic 9-THC administration in this region.
Due to eﬀects such as these, the present study examined the
expression of CB1R and the expression of AHA1 and HSP90β
in both hippocampus and striatum following chronic 9-THC.
The role of AHA1 in cannabinoid signaling was ﬁrst pointed out
by Filipeanu et al. (2011), and they showed that its expression in
vivo was increased by both chronic 9-THC and OVX. Further,
altering AHA1 expression in vitro demonstrated that this protein
was a chaperone of CB1R (but not of CB2R), as overexpression
of AHA1 was found to enhance plasma membrane levels of
CB1R, enhance CB1R-mediated reductions in cyclic adenosine
monophosphate (cAMP), and increase 9-THC-mediated
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activation of MAPK through CB1R. Before this study, the only
known role of AHA1was as a co-activator of HSP90, a heat-shock
protein involved in protein folding, traﬃc, and degradation
(Wandinger et al., 2008). However, HSP90 levels in the
cerebellumwere not changed by chronic9-THC administration
during adolescence. The research plan for the present study was
to extend those observations to the hippocampus and striatum,
areas that are also important contributors to learning and
performance behavior. Further, no studies to our knowledge have
investigated the eﬀects of chronic 9-THC and hormone status
on these proteins in females for the duration used in this study.
Brain-derived neurotrophic factor (BDNF) expression was of
interest because of all of the data indicating that there is impaired
neuronal plasticity in the hippocampus when chronic 9-THC
is initiated during adolescence (Volkow et al., 2014), and both
chronic 9-THC and estrogen interact with this trophic factor
(Butovsky et al., 2005; Scharfman and Maclusky, 2005; Maj et al.,
2007; De Chiara et al., 2010).
Materials and Methods
Subjects
A total of 71 female Long-Evans rats served as subjects. With
respect to hormonal status, 35 were OVX, whereas the other 36
underwent sham surgery (intact). These two hormone groups
were then further subdivided into groups that received either
chronic saline or 9-THC, yielding four treatment groups
with respect to hormonal status and chronic administration
(i.e., intact/saline, intact/THC, OVX/saline, and OVX/THC). An
additional variable was whether chronic administration of saline
or 9-THC began during adolescence or early adulthood. For
the behavioral experiments, 24 females received saline or 9-
THC from adolescence [postnatal day (PD) 35] onward, whereas
another 24 received saline or 9-THC from early adulthood
(PD 75) onward. The remaining 23 females received all of the
experimental manipulations, but were used solely for analyses of
pharmacodynamics variables (e.g., receptor levels).
The female rats were purchased from a commercial vendor
(Harlan Sprague Dawley, Indianapolis, IN, USA) in two cohorts
as pups and arrived at the Animal Care facility on PD 21. Pups
were group housed until PD 30 and provided a standard diet
of rodent chow (Rodent Diet 5001, PMI Inc., St. Louis, MO,
USA) and water ad libitum. On PD 30, all the subjects underwent
either OVX or a sham surgery. Following these procedures, the
subjects were individually housed in polypropylene plastic cages
with hardwood chip bedding. Food restriction was also instituted
at this time to maintain the compatibility of the treated groups,
as OVX females have been shown to gain weight at a faster rate
than intact females (e.g., Winsauer et al., 2011a); in this case,
subjects were maintained at approximately 90% of their free-
feeding weights while allowing for aminimum gain of 5–10 grams
per week to control for normal growth.
The colony room was maintained at 21 ± 2◦C with 50 ± 10%
relative humidity on a 14L:10D light/dark cycle (lights on 06:00 h,
lights oﬀ 20:00 h) throughout testing. All subjects were also
maintained in accordance with the Institutional Animal Care
and Use Committee, Louisiana State University Health Sciences
Center, and in compliance with the recommendations of the
National Research Council in the Guide for the Care and Use of
Laboratory Animals (National Research Council, 1996).
Adolescent Ovariectomies
As indicated above, 35 subjects were OVX while under general
anesthesia induced by intraperitoneal (i.p.) injection of ketamine
(50 mg/kg) and xylazine (10 mg/kg), as detailed inWinsauer et al.
(2011a). The remaining females underwent sham surgeries as a
control for the ovariectomy. During sham surgeries, the subjects
were anesthetized with ketamine/xylazine, shaved, and bilateral
ﬂank incisions were made, but the ovaries were not isolated or
removed. Female rats generally recover from both procedures
fully within 2 days after surgery, and this was evident from
their activity levels, food and water intake, and urination and
defecation.
Chronic Administration of Saline or 9-THC
Whether chronic administration began on PD 35 or PD 75, the
chronic regimen consisted of either a single, daily injection of
saline or 0.56 mg/kg of9-THC. This injection was administered
at the beginning of each day, 7 days per week, with the exception
of a brief period (∼21 days) for a large number of adolescents
and a small number of adults to facilitate training the behavioral
groups. During this brief period, injections were administered in
the early afternoon after their training sessions. Throughout the
rest of the study (164 days for the adolescents and 124 days for
the adults), injections were administered in the morning prior to
testing the two groups of 12 animals, which had subjects from
each age and treatment group to control for the time from the
chronic injection.
The 9-THC was obtained from the National Institute on
Drug Abuse (Research Technical Branch, Rockville, MD, USA),
and arrived in a 100% ethanol solution at a concentration
of either 100 or 200 mg/ml. These concentrations were then
partitioned into smaller aliquots (e.g., 50 mg), lyophilized by
high-speed vacuum, and then stored at −20◦C. When needed,
the aliquots of 9-THC were reconstituted for injection as an
emulsion using ethanol, emulphor (Alkamuls EL-620, Rhodia,
Inc., Cranbury, NJ, USA), and saline in a proportion of 1:1:18,
respectively. The volume for both saline and 9-THC injections
was 0.1 ml/100 g body weight. Given this injection volume, the
percentage of ethanol (5%) in the vehicle had no behavioral
consequences. For example, the injection volume for a 260 g
rat was 0.26 ml, and 5% of 0.26 ml is 0.013 ml, which equals
0.01 g of ethanol when 0.013 ml is multiplied by the density of
ethanol at standard temperature and pressure (0.789 g/ml). This
0.01 g divided by the weight of the rat (0.26 kg) yields a 0.04-g/kg
dose of ethanol, which is substantially below an eﬀective dose for
ethanol.
Apparatus for Behavioral Testing
Twelve identical modular test chambers (Coulbourn
Instruments, Allentown, PA, USA, Model E10-10TC) conﬁgured
speciﬁcally for rodents were used, and have been described
in detail previously (Winsauer et al., 2011a). Brieﬂy, located
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on the front wall of each chamber were a houselight, speaker,
auditory feedback relay, pellet trough (5.5 cm above the ﬂoor
and centered), and three response keys aligned horizontally
(8 cm apart, center to center, and 14.5 cm above the ﬂoor). Each
response key could be transilluminated by three Sylvania 28PSB
indicator lamps, one with a red plastic cap, one with a yellow cap,
and one with a green cap. Correct responses produced an audible
click of the feedback relay. Each chamber was enclosed within
a sound-attenuating cubicle equipped with a fan for ventilation
and white noise to mask extraneous sounds. All test chambers
were connected to a computer programmed in MED-PC for
Windows, Version IV (MED Associates, Inc., St. Albans, VT,
USA), and to cumulative recorders (Gerbrands, Arlington, MA,
USA) located within the same room.
Behavioral Procedure
As diagramed in Figure 1, training both the adolescent and adult
groups to respond under the behavioral procedure began 10 days
after the onset of chronic saline or 9-THC administration,
which was PD 45 for the adolescents and PD 85 for the
adults. Because training was initiated later for the adults, the
adult groups were handled and weighed each day to maintain
some compatibility between the adolescents and the adults in
terms of their interaction with the experimenter. This amounted
to acclimating them to being held by the experimenter for
increasing durations, and placing them in an empty cage located
on an electronic balance to obtain their daily weight.
Preliminary training of the subjects to respond (i.e., nose
poke) on a key in the apparatus, and to acquire a three-
response sequence on a daily basis (i.e., repeated acquisition),
has been described previously (Gerak et al., 2004). Ultimately,
the goal of this multiple-schedule procedure was to have the
subjects acquire a diﬀerent three-response sequence each session
in the acquisition components and respond on an invariant
or well-rehearsed sequence in the performance components.
After this preliminary training was completed, a multiple
schedule with repeated acquisition and performance components
was instituted. Whether in the acquisition or performance
component, each subject’s task was to respond on the correct key
in the presence of one of three stimulus colors (e.g., keys green,
center correct; keys red, left correct; keys yellow, right correct).
When the response sequence was completed by emitting three
correct responses (i.e., one correct response in the presence of
each color), the key lights were extinguished and the stimulus
light in the pellet trough was illuminated for 0.4 s. Subsequently,
the response keys were illuminated with the ﬁrst stimulus
(i.e., green) and the sequence was reset. Sequence completions
were maintained by food presentation under a second-order
ﬁxed-ratio (FR) three schedule, as every three completions of
the sequence resulted in the presentation of a 45-mg food
pellet (Purina Mills TestDiet, Richmond, VA, USA). When rats
responded on an incorrect key (in the example above, the left or
right key when the green lights were illuminated), the error was
followed by a 5-s period in which the keylights were extinguished
and responses had no programmed consequence (i.e., a timeout).
To establish a steady state of repeated acquisition, the
sequence in the acquisition components was changed from
session to session (i.e., daily). An example of sequences for
ﬁve consecutive sessions was: C–L–R, L–R–C, C–R–L, R–L–
C, and L–C–R. The sequences were carefully selected to be
equivalent in several ways, and there were restrictions on their
ordering across sessions. Brieﬂy, each sequence was scheduled
with equal frequency and consecutive correct responses within
a sequence were scheduled on diﬀerent keys. Occasionally, a
FIGURE 1 | Timeline of manipulations for the two age groups of female subjects that were administered chronic 9-THC after either ovariectomy
(OVX) or a sham operation.
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correct sequence position for a given color was the same for two
consecutive sessions (as in the list of sequences above, L–R–C and
C–R–L).
During performance components, the houselight and the
response keys were illuminated. The houselight served as a
discriminative stimulus for responding during this component,
and unlike the acquisition component, the sequence in this
component remained the same from session to session (i.e., R-C-
L). Experimental sessions always began with an acquisition
component, which then alternated with a performance
component after 40 reinforcers or 20 min, whichever occurred
ﬁrst. Each session terminated after 150 reinforcers or 80 min,
whichever occurred ﬁrst. Throughout testing, sessions were
generally conducted 5 days per week, Monday through Friday.
Dose-Effect Determinations of 9-THC or
Rimonabant during Chronic 9-THC or Saline
Administration
When the response rate and the percentage of errors varied
by less than 20% of the mean for 10 consecutive days, dose-
eﬀect curves for 9-THC and rimonanbant were determined
by replacing the chronic saline or 9-THC injection with a
diﬀerent dose every 3 or 4 days. The presession administration
time for both drugs was always 30 min, and the doses tested
ranged from ineﬀective to one that substantially decreased overall
response rate or eliminated responding entirely. As a control
for these acute 9-THC or rimonabant injections, saline or
vehicle injections were also administered occasionally, 30 min
prior to the start of the session. The vehicle for rimonabant was
comprised of ethanol (33.33%), emulphor (33.33%), and saline
(33.33%).
Western Blotting
Subjects from the groups for the pharmacodynamics studies
were sacriﬁced prior to the determination of the 9-THC
and rimonabant dose-eﬀect curves in the behavioral groups
to yield an understanding of the neuronal protein levels that
resulted from the chronic dose alone. The behavioral groups
were sacriﬁced after the determination of dose-eﬀect curves for
both 9-THC and rimonabant in each treatment group. At the
respective time points, subjects from each treatment group were
sacriﬁced in pairs for analysis of hippocampal protein expression.
To control for the eﬀects of circulating levels of endogenous
hormones across the estrous cycle, each gonadally intact female
was sacriﬁced with one OVX female from the respective chronic
groups (saline or 9-THC) when the gonadally intact member
of the pair was in proestrus (i.e., every intact/THC was paired
with a OVX/THC, and every intact/saline was paired with a
OVX/saline). The hippocampus and striatum were separated
from the rest of the brain using the procedure described by
Glowinski and Iversen (1966), and levels of CB-1, Heat-shock
protein 90 beta (HSP90β), heat-shock 90 kDA protein ATPase
homolog 1 (AHA-1), and BDNF were determined by western
blot analyses of homogenate. Western-blot analysis of protein
expression was carried out as previously described (Winsauer
et al., 2011a, 2012). Brieﬂy, the samples were separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), followed by transfer onto polyvinylidene ﬂuoride (PDVF)
membranes. The primary antibodies used were anti-CB1 receptor
(polyclonal antibody, item #101500, Cayman Chemical, Ann
Arbor, MI, USA), anti-AHA1 (monoclonal antibody, catalog
number H00010598-M01, AbNova, Taipei City, Taiwan), anti-
HSP90β (monoclonal antibody, item K3705, Enzo Life Sciences,
Inc., Farmingdale, NY, USA), anti-BDNF antibody (polyclonal
antibody, SC-546, Santa Cruz Biotechnology, Dallas, TX, USA),
and anti-β-Actin (monoclonal antibody, SC-47778, Santa Cruz
Biotechnology, Dallas, TX). The secondary antibodies used
were anti-rabbit and anti-mouse, both of which were HRP-
labeled (Perkin-Elmer, Waltham, MA, USA). The protein levels
were visualized using a GE ImageQuant image analyzer (LAS-
4000) and quantiﬁed using the Image J program (Version
1.48).
Data Analyses
The body-weight data from the four treatment groups were
compared using a three-way ANOVA with hormone condition
and chronic treatment considered to be between-group factors
and the phase of the experiment as a repeatedmeasure (SigmaStat
Statistical Software, SYSTAT Software, Inc., Point Richmond, CA,
USA). If signiﬁcant interactions occurred, two-way and one-
way ANOVA tests were conducted where appropriate, and these
tests were followed by Holm–Sidak post hoc tests to determine
diﬀerences between the treated groups and the untreated control
group. Signiﬁcance was accepted at an α level ≤0.05 for all
statistical tests.
Responding in the acquisition and performance components
of the multiple-schedule procedure was analyzed in terms
of: (1) the overall response rate (total responses/min,
excluding timeouts), and (2) the overall accuracy, expressed
as the percentage of errors [(incorrect responses/total
responses) × 100]. However, when a dose of 9-THC reduced
the overall response rate to less than ﬁve responses per minute,
the percentage of errors produced by that dose was not calculated
due to the small number of responses involved. To determine
if there were any statistical diﬀerences among the groups in
terms of their baseline behavior, data obtained after saline
administration (i.e., the control data) were analyzed separately
from the drug data using a two-way ANOVA with both hormone
status and chronic treatment serving as between-subject factors.
Diﬀerences in adult sensitivity to 9-THC or rimonabant were
determined by statistically comparing the dose-eﬀect data that
resulted from the acute administration of either 9-THC or
rimonabant. For each drug, the dose-eﬀect curves for each
treatment group were analyzed using a two-way ANOVA with
chronic treatment serving as the between-subjects factor and
dose serving as the repeated measure. Signiﬁcant main eﬀects
for dose were analyzed further by Holm–Sidak post hoc tests
that compared the eﬀects of various doses on response rate
and the percentage of errors with the respective control values.
Signiﬁcant interactions were further analyzed by appropriate
one-way ANOVA tests for each factor and Holm–Sidak post hoc
tests.
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Western blot quantiﬁcations were analyzed by a two-way
ANOVA for each protein and each brain region, with hormone
status and chronic treatment serving as factors. Signiﬁcant main
eﬀects for each factor were analyzed by Holm–Sidak post hoc
tests. When a signiﬁcant interaction occurred, one-way ANOVA
tests were conducted on each factor to determine signiﬁcant
diﬀerences.
Eﬀects of hormonal status and chronic 9-THC on behavior
were also quantiﬁed by comparing the ED50 values and the slopes
of the regression lines used to determine the ED50 values. For
response rate, the ED50 values represented the estimated dose of
9-THC that decreased responding from control levels by 50%.
For the percentage of errors, the ED50 values represented the
estimated dose of9-THC that increased the percentage of errors
150%, or 50% above control levels.
Results
Effects of Chronic Saline or 9-THC on
Behavioral Training
As shown in Table 1, the number of training days did
not signiﬁcantly diﬀer among the treatment groups for each
age (adult versus adolescent), as there was no eﬀect of
hormone condition [F(1,40) = 0.71, p > 0.05], chronic
treatment [F(1,40) = 0.01, p > 0.05], or interactions between
any of three experimental factors [age × hormone status:
F(1,40) = 1.39, p > 0.05; age × chronic treatment: F(1,40) = 0.5,
p > 0.05; hormone status × chronic treatment: F(1,40) = 2.09,
p > 0.05; age × hormone status × chronic treatment:
F(1,40) = 3.68, p > 0.05]. However, there was a small, but
signiﬁcant, eﬀect of age on the number of training days
[F(1,40) = 20.02, p < 0.001], with adolescents taking slightly
longer to train than adults. This was not surprising in that the
chronic 9-THC injections for more of the adolescents than
the adults had to be moved temporarily to the afternoon, as
morning injections markedly disrupted training. Nevertheless,
the ﬁnal pattern of responding in the acquisition component
had to be characterized by a decrease in the number of
errors and an increase in consecutive correct completions
of the response sequence each day, as within-session error
reduction essentially deﬁned sequence acquisition. There was
TABLE 1 | Mean number of days required to train the subjects under the
behavioral procedure during chronic administration.
Treatment group Adult Adolescent
Intact/saline 37 ± 2.2a 42.5 ± 1.3b
Intact/THC 37.2 ± 1.0a 45.7 ± 1.9b
OVX/saline 36.8 ± 1.5a 44.2 ± 1.5b
OVX/THC 38.2 ± 1.5a 39 ± 1.6b
Mean 37.3 ± 0.84 42.8 ± 0.95
For each treatment group, superscript letters indicate significant differences
between ages, but not between hormone status or chronic treatment (e.g., mean
group weights designated with a superscript “a” are similar to each other, but
significantly different from “b”).
also a notable diﬀerence in the response patterns for the
two components, as sequence acquisition was not required
in the performance component (i.e., the percentage of errors
was typically larger in the acquisition component than in the
performance component).
Effects of Chronic Saline or 9-THC on the
Baseline of Behavior
The top panels of Figure 2 show that chronic 9-THC
decreased the response rate irrespective of age in both
components of the procedure compared with chronic saline.
This was veriﬁed statistically by main eﬀects for chronic
treatment in the acquisition [F(1,40) = 9.48, p = 0.004]
and performance [F(1,40) = 9.65, p = 0.003] components.
Interestingly, these rate-decreasing eﬀects occurred even though
the majority of the chronic injections of saline or 9-THC
were administered during the morning hours and behavioral
sessions occurred serially after that time. There were no
signiﬁcant main eﬀects for age [acquisition: F(1,40) = 0.16,
p > 0.05, performance: F(1,40) = 0.29, p > 0.05] or hormone
condition [acquisition: F(1,40) = 0.21, p > 0.05, performance:
F(1,40) = 0.52, p > 0.05], and no signiﬁcant interaction
for age × chronic treatment [acquisition: F(1,40) = 0.11,
p > 0.05, performance: F(1,40) = 0.004, p > 0.05] or hormone
status × chronic treatment [acquisition: F(1,40)= 0.02, p> 0.05,
performance: F(1,40) = 0.11, p > 0.05] or age × hormone
status × chronic treatment [acquisition: F(1,40)= 0.02, p> 0.05,
performance: F(1,40) = 0.007, p > 0.05]. There was, however,
a signiﬁcant interaction between age × hormone status in both
components [acquisition: F(1,40) = 4.85, p = 0.03, performance:
F(1,40) = 5.80, p = 0.021], which reﬂected the general ﬁnding
that the intact adult groups had higher response rates than the
intact adolescent groups, whereas the OVX adult groups had
lower response rates than the OVX adolescent groups irrespective
of chronic treatment.
With regard to the percentage of errors emitted (Figure 2,
bottom panels), chronic 9-THC produced a higher baseline
error rate than chronic saline. This was indicated statistically
by signiﬁcant main eﬀects for chronic treatment in the
acquisition [F(1,40) = 7.75, p = 0.008] and performance
[F(1,40) = 12.18, p = 0.001] components, in the absence of
signiﬁcant main eﬀects for age [acquisition: F(1,40) = 0.23,
p > 0.05, performance: F(1,40) = 0.00, p > 0.05] or
hormone status [acquisition: F(1,40) = 2.69, p > 0.05,
performance: F(1,40) = 3.86, p = 0.056] or of any interactions
between these factors in acquisition [age × hormone
status: F(1,40) = 0.20, p > 0.05, age × chronic treatment:
F(1,40) = 0.003, p > 0.05, hormone status × chronic treatment:
F(1,40) = 1.47, p > 0.05, age × hormone status × chronic
treatment: F(1,40) = 0.26, p > 0.05] or performance
[age × hormone status: F(1,40) = 0.51, p > 0.05, age × chronic
treatment: F(1,40) = 0.71, p > 0.05, hormone status × chronic
treatment: F(1,40) = 2.68, p > 0.05, age × hormone
status × chronic treatment: F(1,40) = 0.03, p > 0.05].
Thus, chronic 9-THC increased errors in the acquisition
and performance components similarly in both age groups and
in both hormone groups.
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FIGURE 2 | Bar graphs showing the effects of hormonal status and
chronic 9-THC administration from either early adulthood
(n = 6/group) or adolescence (n = 6/group) on baseline response rates
and percent errors under the multiple schedule of repeated acquisition
and performance of response sequences. These data represent the grand
mean for 6–20 occasions in each subject when an injection of saline was
substituted for the daily chronic dose of 9-THC. The first of these occasions
occurred after a minimum of 65 days after chronic 9-THC in each age group
(early adult or adolescent). As shown by the horizontal bars and letters, there
was a significant main effect of chronic 9-THC on both response rate and
percent errors in each component, but no effect of hormone status and no
interaction between chronic 9-THC and hormone status.
Effects of 9-THC in Mature Intact and OVX
Females Administered Saline Chronically from
Early Adulthood (PD 75)
In these 9-THC-naïve adults, 0.32–3.2 mg/kg of 9-THC
produced dose-dependent rate-decreasing and error-increasing
eﬀects in the acquisition and performance components with
only modest eﬀects of hormone status evident for response rate
in the performance component (Figure 3A). These ﬁndings
were supported by the statistical analyses, which indicated that
there was a main eﬀect of 9-THC dose for both response
rate and the percentage of errors in both the acquisition [rate:
F(5,50) = 52.65, p < 0.001; errors: F(5,41) = 7.99, p < 0.001]
and performance [rate: F(5,50) = 29.89, p < 0.001; errors:
F(5,42) = 7.38, p < 0.001] components, with only a signiﬁcant
interaction between 9-THC dose and hormone status for
response rate in the performance component [F(5,50) = 2.60,
p = 0.036]. Otherwise, there was no signiﬁcant main eﬀects of
hormone status for either dependent measure in the acquisition
[rate: F(1,50) = 0.03, p > 0.05; error: F(1,41) = 0.15, p > 0.05]
and performance [rate: F(1,50) = 0.04, p > 0.05; error:
F(1,42) = 0.37, p > 0.05] components, and no interaction
between hormone status and 9-THC dose [acquisition: rate,
F(5,50) = 2.39, p = 0.051; error, F(5,41) = 1.36, p > 0.05,
performance: error, F(5,42) = 1.16, p > 0.05]. In terms of
dosages, the 1- to 3.2-mg/kg doses were signiﬁcantly diﬀerent
from acute saline (control) injections for both response rate and
percent errors in the acquisition components and for percent
errors in the performance component. Due to the interaction
between 9-THC dose and hormone status for response rate
in the performance component, the 1 to 3.2-mg/kg doses were
signiﬁcantly diﬀerent from acute saline (control) injections for
the intact group, but only the 1.8 and 3.2 mg/kg doses were
signiﬁcantly diﬀerent for the OVX group. Another indication of
the eﬀect of hormone status on response rate in the performance
component was the greater than twofold shift in the ED50
value for the OVX group compared with the intact group (see
Table 2).
Effects of 9-THC in Mature Intact and OVX
Females Administered 9-THC Chronically
from Early Adulthood (PD 75)
Figure 3B shows the eﬀects of acute 9-THC in 9-THC-
experienced adults. In these intact and OVX groups, acute
9-THC produced only dose-dependent rate-decreasing eﬀects
in the acquisition and performance components; there were
no signiﬁcant error-increasing eﬀects. Furthermore, these rate-
decreasing eﬀects occurred at doses that were 10-folds higher
than those that decreased rate in the hormone groups chronically
administered saline (compare 3A and 3B, and Table 2). All of
these observations were supported by the statistical analyses,
which indicated that there was a main eﬀect of 9-THC dose
in both behavioral components [acquisition: F(9,86) = 16.50,
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FIGURE 3 | Acute effects of 9-THC in intact and OVX females that
received either saline (A, upper four panels) or 5.6 mg/kg of 9-THC
(B, lower four panels) daily from early adulthood to sacrifice and that
were responding under an acquisition (A, graph legend) and
performance (P, graph legend) procedure. Data points and vertical lines
above C in each panel indicate the grand mean and standard error of the mean
(SEM) for 9–19 saline (control) injections. The data points and vertical lines in the
dose-effect curves represent a grand mean and SEM for that dose, as each
dose was administered on 2–4 occasions in each subject. Asterisks alone or in
combination with brackets indicate significant differences between particular
doses of 9-THC and acute saline (control) injections. Numerical values in
parentheses and adjacent to a data point indicate the number of subjects
represented by that point when it differed from the total number of subjects for
that group (e.g., instances in which responding was eliminated entirely and the
percentage of errors could not be calculated, or simply differences in the
potency of 9-THC across subjects).
p < 0.001, performance: F(9,86) = 13.86, p < 0.001], but
no signiﬁcant main eﬀect of hormone status [acquisition:
F(1,86) = 2.04, p > 0.05, performance: F(1,86) = 0.98,
p > 0.05] and no signiﬁcant interaction between these two
factors [acquisition: F(9,86) = 0.35, p > 0.05, performance:
F(9,86) = 0.74, p > 0.05]. The similarity of the eﬀects on
response rate across the two hormone groups and across the two
behavioral tasks was also evident in the post hoc analyses of the
grouped data, which found that only the 10–32-mg/kg doses were
signiﬁcantly diﬀerent from control in the acquisition component,
and only the 18–32-mg/kg doses were diﬀerent from control in
the performance component.
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TABLE 2 | Effective 9-THC dose (i.e., ED50s) for decreasing response rate by 50% and increasing the percentage of errors by 50% in female rats
chronically administered saline or 9-THC from early adulthood or adolescence, as calculated from a linear regression.
ED50 (mg/kg) Acquisition component Performance component
Resp. Rate (slope) Percent error (slope) Resp. Rate (slope) Percent error (slope)
Chronic admin. from adulthood
Intact/saline 1.24 (−13.38) 0.95 (11.28) 1.57 (−11.84) 1.32 (1.73)
Intact/THC 24.15 (−5.33) – (0.29) >32.0 (−4.84) – (−0.06)
OVX/saline 1.97 (−9.31) 0.77 (4.98) 3.89 (−7.55) 1.32 (2.29)
OVX/THC 19.19 (−4.89) – (0.55) 22.39 (−9.85) – (10.89)
Chronic admin. from adolescence
Intact/saline 1.77 (−4.32) 0.77 (5.39) 3.76 (−3.39) 0.60 (4.67)
Intact/THC 29.44 (−2.83) – (8.16) >56.0 (−1.61) – (0.16)
OVX/saline 1.62 (−8.19) 0.73 (5.34) 2.83 (−7.44) 0.66 (4.12)
OVX/THC 6.15 (−6.12) 5.12 (10.82) 7.11 (−6.54) 4.40 (9.12)
A dash (-) indicates values that could not be calculated because a 50% decrease (response rate) or increase (percentage of errors) was not obtained.
The absence of error-increasing eﬀects in the 9-THC-
experienced intact and OVX groups was also veriﬁed statistically
in that there were no signiﬁcant main eﬀects for either 9-
THC dose [acquisition: F(9,80) = 0.71, p > 0.05, performance:
F(9,80) = 1.24, p > 0.05] or hormone status [acquisition:
F(1,80) = 1.69, p > 0.05, performance: F(1,80) = 1.67, p > 0.05],
and no signiﬁcant interactions between factors [acquisition:
F(9,80) = 1.22, p > 0.05, performance: F(9,80) = 1.20, p > 0.05]
in either component. Based on the near-zero slopes of the dose-
eﬀect curves and the fact that none of the doses produced a 50%
increase in errors, there are no ED50 values for these groups in
Table 2.
Effects of 9-THC in Mature Intact and OVX
Females Administered Saline Chronically from
Adolescence (PD 45)
Acute 9-THC in these 9-THC-naïve intact and OVX groups
produced similar, but not identical, eﬀects to those in the 9-
THC-naïve hormone groups chronically administered saline
from early adulthood (cf. Figures 3A and 4A); the diﬀerence
across these groups experimentally was the age at which chronic
saline administration began (PD 75 versus PD 45) and age at
which acute 9-THC was administered to establish these dose-
eﬀect curves (PD 141 versus PD 101). The diﬀerence in eﬀect
was that acute9-THCwas slightly less potent in these9-THC-
naïve groups, as almost all of the subjects in each group were able
to receive 5.6 mg/kg, and this led to some hormone-dependent
variations in the error-increasing eﬀects (i.e., percent errors could
only be calculated for 2 of the 6 OVX subjects because their
individual response rates were below 5 responses/min).
When the data for response rate were analyzed statistically,
there were signiﬁcant main eﬀects for the dose of 9-THC
in both behavioral components [acquisition: F(6,58) = 27.71,
p< 0.001, performance: F(6,58)= 21.25, p< 0.001], but no main
eﬀects for hormone status [acquisition: F(1,58) = 1.15, p > 0.05,
performance: F(1,58) = 2.06, p > 0.05]. In the acquisition
component, however, there was a signiﬁcant dose × hormone
interaction [F(6,58) = 2.26, p = 0.05] largely due to a signiﬁcant
diﬀerence between hormone groups at the 0.56-mg/kg dose.
The interaction was not signiﬁcant for the responding in the
performance component [F(6,58) = 2.17, p = 0.059]. Regardless
of the component, post hoc tests indicated that doses of 9-THC
from 1 to 5.6 mg/kg produced decreases in response rate that
were signiﬁcantly diﬀerent from control injections. Finally, the
similarity of the rate-decreasing eﬀects of 9-THC in these two
9-THC-naïve hormone groups was reﬂected in the similarity of
the ED50 values for the two groups in each behavioral component
(Table 2).
The bottom panels of Figure 4A show the error-increasing
eﬀects produced by 9-THC in both behavioral components and
the signiﬁcant main eﬀects for dose [acquisition: F(6,47)= 12.09,
p < 0.001, performance, F(6,49) = 9.69, p < 0.001]. As
mentioned above, there were also signiﬁcant dose × hormone
interactions in both components [acquisition: F(6,47) = 4.16,
p = 0.002, performance: F(6,49) = 3.48, p = 0.006], but no
main eﬀects of hormone status [acquisition: F(1,47) = 0.43,
p > 0.05, performance: F(1,49) = 2.93, p > 0.05]. In
the acquisition components, 1–5.6 mg/kg increased errors
signiﬁcantly compared to control in the intact group, whereas
1–3.2 mg/kg increased errors signiﬁcantly in the OVX group.
The 5.6 mg/kg did not increase errors signiﬁcantly in the OVX
group because only one of the two females that were able to
respond above 5 responses/min had a marked increase in the
percentage of errors. With respect to the percentage errors in
the performance component, the 1-, 1.8-, and 5.6-mg/kg doses
of 9-THC increased errors signiﬁcantly compared to control in
the intact group, but only the 1.8-mg/kg dose reliably increased
errors signiﬁcantly in the OVX group. Despite these statistical
interactions between 9-THC dose and hormone status in
these 9-THC-naïve hormone groups, the ED50 values for the
percentage of errors in each component were remarkably similar
(Table 2).
Effects of 9-THC for Mature Intact and OVX
Females Administered 9-THC Chronically
from Adolescence
These particular 9-THC-experienced hormone groups were:
(1) less sensitive to the rate-decreasing and error-increasing
Frontiers in Pharmacology | www.frontiersin.org 9 July 2015 | Volume 6 | Article 133
Winsauer et al. Hormonal status, age, and THC in females
FIGURE 4 | Acute effects of 9-THC in intact and OVX females that
received either saline (A) or 5.6 mg/kg of 9-THC (B) daily from
adolescence to sacrifice and that were responding under an
acquisition and performance procedure. Data points and vertical lines
above C in each panel indicate the grand mean and SEM for 6–20 saline
(control) injections. Asterisks alone or in combination with brackets indicate
significant differences between particular doses of 9-THC and acute saline
(control) injections, whereas a cross indicates a significant difference between
hormone groups at a particular dose. For additional details, see legend for
Figure 3.
eﬀects of acute 9-THC than either of the two sets of 9-THC-
naïve hormone groups as expected (Figures 3A and 4A), (2)
more sensitive than the hormone groups that received 9-THC
chronically from early adulthood (PD 75) onward (Figure 3B),
and (3) diﬀerent from each other. Especially evident was the
increased sensitivity of the OVX group that initiated chronic 9-
THC during adolescence compared to the sensitivity of the OVX
group that initiated chronic 9-THC during early adulthood
(compare Figures 3B and 4B). For example, in the OVX group
that began 9-THC during adolescence, 5.6 and 10 mg/kg
signiﬁcantly decreased response rate and 10 mg/kg increased
percent errors in both behavioral components. In the OVX
group that began 9-THC during early adulthood, 10 mg/kg
produced only a small, but signiﬁcant, decrease in response rate
and there were no error-increasing eﬀects at any dose tested (see
Figure 3B).
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When these intact and OVX groups with 9-THC experience
from adolescence onward were analyzed statistically, there
were main eﬀects of dose on both response rate [acquisition:
F(8,74) = 10.86, p < 0.001, performance: F(8,74) = 7.73,
p < 0.001] and percent errors [acquisition: F(8,66) = 4.96,
p < 0.001, performance: F(8,66) = 3.87, p < 0.001] in
both components, and a signiﬁcant dose × hormone status
interaction for response rate in the acquisition component
[F(8,74) = 2.32, p = 0.03]. No other interactions were signiﬁcant
[acquisition/errors: F(8,66) = 1.43, p > 0.05, performance/rate:
F(8,74) = 1.92, p > 0.05, performance/errors: F(8,66) = 1.65,
p > 0.05], and there were no main eﬀects of hormone status on
response rate [acquisition: F(1,74)= 1.05, p> 0.05, performance:
F(1,74) = 1.41, p > 0.05] or percent errors [acquisition:
F(1,66) = 1.0, p > 0.05, performance: F(1,66) = 0.51, p > 0.05].
The diﬀerence in 9-THC potency between these 9-THC-
experienced hormone groups was even more evident from the
ED50 values than the statistical analyses. For response rate, the
respective ED50 values for the intact and OVX groups were 29.44
and 6.15 for the acquisition component and >56 and 7.11 for
the performance component. For percent error, the diﬀerence in
potency was reﬂected in the fact that 9-THC did not produce
a 50% increase in errors in the intact group, whereas the ED50
values for the OVX groups in the acquisition and performance
components were 5.12 and 4.40 mg/kg, respectively (see
Table 2).
Effects of Rimonabant in Mature Intact and
OVX Females Administered Saline or 9-THC
Chronically from Adolescence or Early
Adulthood
Given that separate analyses indicated that there were only
minor diﬀerences in the eﬀects of rimonabant for the
groups that initiated 9-THC during adolescence and early
adulthood, the data for the two ages were combined. As
shown in Figure 5, rimonabant (0.32–10 mg/kg) produced
relatively consistent rate-decreasing and error-increasing eﬀects
in all four treatment groups. However, rimonabant aﬀected
response rate and percent errors diﬀerently. For response
rate, diﬀerences in the potency of rimonabant’s eﬀects were
reﬂected by signiﬁcant dose × treatment interactions in both
the acquisition [F(12,144) = 3.58, p < 0.001] and performance
[F(12,144) = 3.52, p< 0.001] components, along with signiﬁcant
main eﬀects of treatment [acquisition: F(3,144)= 4.04, p= 0.014,
performance: F(3,144) = 3.24, p = 0.033] and rimonabant
dose [acquisition: F(4,144) = 74.93, p < 0.001, performance:
F(4,144) = 54.19, p < 0.001]. In contrast, for percent error,
there were no diﬀerences in potency among the groups,
as there were only main eﬀects of treatment [acquisition:
F(3,135) = 6.08, p = 0.002, performance: F(3,138) = 6.78,
p < 0.001] and rimonabant dose [acquisition: F(4,135) = 39.49,
p < 0.001, performance: F(4,138) = 18.82, p < 0.001]; the
dose× treatment interactions were not signiﬁcant for responding
in either component [acquisition: F(12,135) = 0.75, p > 0.05,
performance: F(12,138) = 0.65, p > 0.05].
Characterizing the disruptive eﬀects of rimonabant was also
complicated by the signiﬁcant diﬀerences in baseline response
rates and percent errors for the groups chronically administered
saline versus 9-THC, and by an overall diﬀerence in the
magnitude of the eﬀects for these groups. For example, the
intact/THC group was the only group for which 0.32 mg/kg
of rimonabant signiﬁcantly decreased response rate in both
components, yet the dose-eﬀect curves for this group had
shallower slopes and larger ED50 values than those for the
groups that received saline chronically. In fact, an ED50 value
could not be calculated for responding in the performance
component because 10 mg/kg of rimonabant did not decrease
rate by 50%.
With respect to percent errors, the potency of rimonabant
varied little from group to group. This was indicated by the fact
that 0.32–10 mg/kg produced signiﬁcant increases in all of the
treatment groups compared to control, and by the similarity of
the slopes of the dose-eﬀect curves for each group (Table 3).
Moreover, due to the similarity of the dose-eﬀect curves for
percent errors, there was less of a disparity between the ED50
values and overall magnitude of the eﬀects for each group.
As shown in Table 3, the rank order of potency with which
rimonabant disrupted accuracy in the acquisition components
was: intact/THC > OVX/THC > intact/saline > OVX/saline;
whereas the rank order of potency with which rimonabant
disrupted accuracy in the performance components was:
OVX/THC > intact/saline > OVX/saline > intact/THC.
Effects of Chronically Administered Saline or
9-THC from Adolescence or Early Adulthood
on Hippocampal CB1R, AHA1, and HSP90β in
Intact and OVX Females
Figure 6 shows that OVX had a larger eﬀect on hippocampal
CB1R levels than chronic 9-THC administration, regardless
of the age at which chronic administration was initiated or
behavioral training occurred. For CB1R, this was indicated by
signiﬁcant main eﬀects for hormone status in the groups that
were behaviorally naïve (i.e., untrained) from adolescence or
early adulthood, and the group that was behaviorally trained
during early adulthood [adolescence/untrained: F(1,8) = 119.62,
p< 0.001; adult/untrained: F(1,7)= 4.42, p> 0.05; adult/trained:
F(1,11)= 8.91, p= 0.012]. There were no signiﬁcant main eﬀects
for chronic treatment [adolescence/untrained: F(1,8) = 0.58,
p > 0.05; adult/untrained: F(1,7) = 4.17, p > 0.05; adult/trained:
F(1,11) = 0.62, p> 0.05] or chronic treatment × hormone status
interactions [adolescence/untrained: F(1,8) = 1.76, p > 0.05;
adult/untrained: F(1,7) = 0.06, p > 0.05; adult/trained:
F(1,11) = 3.14, p > 0.05].
Similar to CB1R, hippocampal levels of AHA1 were
signiﬁcantly aﬀected by hormone status, but not chronic 9-
THC, and this was again indicated by signiﬁcant main eﬀects
of hormone status in all three groups [adolescence/untrained:
F(1,8) = 400.72, p < 0.001; adult/untrained: F(1,7) = 8.67,
p = 0.022; adult/trained: F(1,11) = 18.82, p = 0.001]. However,
the age at which chronic treatment was initiated produced
opposite eﬀects. Compared to the respective intact groups,
OVX decreased AHA1 levels in the groups chronically treated
from adolescence onward and increased AHA1 levels in both
cohorts chronically administered9-THC from early adulthood.
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FIGURE 5 | Acute effects of rimonabant in intact and OVX females
that received either saline (A) or 5.6 mg/kg of 9-THC (B) daily from
adolescence or early adulthood to sacrifice and that were responding
under an acquisition and performance procedure. The data for the two
age groups were combined as there was no marked difference between
these age groups. Data points and vertical lines above C in each panel
indicate the grand mean and SEM for 3–10 vehicle (control) injections
administered to each subject in each treatment group. In the upper panels
(response rate), asterisks alone or in combination with brackets indicate
significant differences between particular doses of 9-THC and acute saline
(control) injections, whereas crosses indicate a significant difference from the
intact/saline group under control conditions or after particular doses of
rimonabant. In the bottom panels (percent errors), there were no significant
interactions, only main effects for dose and treatment group. Therefore, the
asterisks with brackets indicate significant differences from control injections
for all of the groups at every dose of rimonabant, whereas the crosses with
brackets indicate the treatment groups that were significantly different from
the intact/saline group irrespective of dose.
TABLE 3 | Effective rimonabant dose (i.e., ED50s) for decreasing response rate by 50% and increasing the percentage of errors by 50% in female rats
chronically administered saline or 9-THC from early adulthood or adolescence, as calculated from a linear regression.
ED50 (mg/kg) Acquisition component Performance component
Treatment group Resp. Rate (slope) Percent error (slope) Resp. Rate (slope) Percent error (slope)
Intact/saline 2.48 (−4.03) 0.98 (2.38) 4.20 (−3.12) 0.56 (1.32)
OVX/saline 3.73 (−3.84) 1.46 (2.00) 6.58 (−3.16) 0.59 (0.46)
Intact/THC 4.83 (−1.57) 0.67 (1.95) – (−0.85) 0.63 (1.67)
OVX/THC 8.02 (−1.70) 0.76 (1.96) – (−1.26) <0.32 (1.05)
A dash (-) indicates values that could not be calculated because a 50% decrease (response rate) was not obtained.
For all three experimental cohorts, there were no signiﬁcant
main eﬀects of chronic treatment [adolescence/untrained:
F(1,8) = 3.12, p > 0.05; adult/untrained: F(1,7) = 0.21,
p > 0.05; adult/trained: F(1,11) = 2.65, p > 0.05] and no
signiﬁcant chronic treatment × hormone status interactions
[adolescence/untrained: F(1,8)= 3.39, p> 0.05; adult/untrained:
F(1,7) = 0.17, p > 0.05; adult/trained: F(1,11) = 2.86, p > 0.05].
The pattern of signiﬁcant eﬀects for hippocampal HSP90β
levels was comparable to that for CB1R and AHA1 levels in that
they were all based on hormone status [adolescence/untrained:
F(1,8) = 24.35, p = 0.001; adult/untrained: F(1,7) = 9.05,
p = 0.02; adult/trained: F(1,11) = 18.38, p = 0.001], but they
were inversely related to those for AHA1; that is, compared
to the intact groups, HSP90β was increased in the OVX
groups chronically treated from adolescence and decreased
in both cohorts chronically administered 9-THC from early
adulthood. As was true for all of the hippocampal AHA1 data,
there were no signiﬁcant main eﬀects of chronic treatment
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FIGURE 6 | Effects of chronic 9-THC and hormone status on the
endogenous levels of CB1R, AHA1, and HSP90β in the
hippocampus. Above each bar graph are western blots of protein levels
in hippocampal extracts from the female rats in each of the four
chronically treated groups. The extracts were separated by 10%
SDS-PAGE, transferred onto PDVF membranes, and subjected to western
blotting with specific antibodies for each protein. The data were quantified
using a GE ImageQuant (LAS-4000 Plus) and the Image J program
(Version 1.54). Levels of each protein were corrected for the β-actin levels
in the same samples and presented as a ratio of protein to actin in
relative units. Asterisks associated with a bar indicate significant main
effects of hormone status, as there were no significant main effects of
chronic treatment and no significant interaction between chronic 9-THC
and hormone status in hippocampus.
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[adolescence/untrained: F(1,8)= 0.16, p> 0.05; adult/untrained:
F(1,7) = 2.57, p > 0.05; adult/trained: F(1,11) = 0.05,
p > 0.05] and no signiﬁcant chronic treatment × hormone status
interactions [adolescence/untrained: F(1,8) = 0.24, p > 0.05;
adult/untrained: F(1,7) = 0.34, p > 0.05; adult/trained:
F(1,11) = 0.73, p > 0.05].
Effects of Chronically Administered Saline or
9-THC from Adolescence or Early Adulthood
on Striatal CB1R, AHA1, and HSP90β in Intact
and OVX Females
The quantiﬁcation of CB1R, AHA1, and HSP90β protein levels
in the striatum yielded substantially diﬀerent results than those
obtained in hippocampus (Figure 7). In particular, these proteins
were not as aﬀected by hormone status, as only CB1R levels in the
groups chronically administered9-THC from adolescence were
signiﬁcantly aﬀected by hormone status alone [F(1,8) = 35.79,
p < 0.001; chronic treatment: F(1,8) = 1.87; p > 0.05;
chronic treatment × hormone status: F(1,8) = 2.54, p > 0.05].
Moreover, there were no signiﬁcant eﬀects on CB1R in either
the untrained [hormone status: F(1,7) = 0.03, p > 0.05; chronic
treatment: F(1,7)= 0.08, p> 0.05; chronic treatment× hormone
status: F(1,7) = 1.22, p > 0.05] or trained [chronic treatment:
F(1,12) = 1.88, p > 0.05; hormone status: F(1,12) = 3.34,
p > 0.05; chronic treatment × hormone status: F(1,12) = 1.13,
p> 0.05] cohorts that received their chronic treatment from early
adulthood onward.
With respect to striatal AHA1 levels, there was a
signiﬁcant chronic treatment × hormone status interaction
for the untrained groups from adolescence [chronic
treatment × hormone status: F(1,8) = 13.44, p = 0.006;
chronic treatment: F(1,8) = 0.55, p > 0.05; hormone status:
F(1,8) = 15.56, p = 0.004] and early adulthood [chronic
treatment × hormone status: F(1,7) = 7.02, p = 0.033; chronic
treatment: F(1,7)= 0.56, p> 0.05; hormone status: F(1,8)= 0.01,
p > 0.05], but no signiﬁcant eﬀect on it in the trained group
that received chronic treatment from early adulthood [chronic
treatment × hormone status: F(1,8) = 0.29, p > 0.05; chronic
treatment: F(1,8)= 0.05, p> 0.05; hormone status: F(1,8)= 0.18,
p > 0.05]. However, the pattern of eﬀects for the interactions was
diﬀerent in the untrained groups. In the groups that received
chronic treatment from adolescence onward, chronic 9-THC
increased AHA1 levels in the intact group [F(1,4) = 12.50,
p = 0.024], but decreased it in the OVX group [F(1,4) = 13.85,
p = 0.02]. Conversely, in the groups that received chronic
9-THC from early adulthood onward, there was no eﬀect in the
intact females [F(1,4) = 1.27, p > 0.05] and a relative increase in
the OVX females [F(1,3) = 26.49, p = 0.014].
The eﬀects of chronic treatment and hormone status
on HSP90β in striatum did not systematically vary
with either AHA1 or CB1R in that there were no
signiﬁcant eﬀects for HSP90β in the untrained groups
from adolescence [hormone status: F(1,8) = 1.18,
p > 0.05; chronic treatment: F(1,8) = 0.82, p > 0.05; chronic
treatment × hormone status: F(1,8) = 0.28, p > 0.05] or early
adulthood [hormone status: F(1,7) = 2.41, p > 0.05; chronic
treatment: F(1,7)= 1.01, p> 0.05; chronic treatment× hormone
status: F(1,7) = 2.92, p > 0.05], but there were signiﬁcant main
eﬀects and a signiﬁcant chronic treatment × hormone status
interaction in the trained adults [hormone status: F(1,8) = 12.55,
p = 0.004; chronic treatment: F(1,8) = 4.81, p = 0.049; chronic
treatment × hormone status: F(1,8) = 17.21, p = 0.001].
Furthermore, in the groups that were trained behaviorally during
early adulthood, the rank order for decreasing HSP90β compared
to control was OVX alone [F(1,6) = 133.51, p < 0.001] ≥ OVX
and 9-THC [F(1,6) = 8.64, p = 0.026] ≥ chronic 9-THC
alone [F(1,6) = 103.87, p < 0.001].
Effects of Chronically Administered Saline or
9-THC from Adolescence or Early Adulthood
on Hippocampal BDNF in Intact and OVX
Females
Figure 8 shows the manner in which hippocampal BDNF
was aﬀected by hormonal status, chronic 9-THC, and age of
initiation. In the groups that received chronic 9-THC from
adolescence onward, there was a signiﬁcant main eﬀect of
hormone status [F(1,8) = 15.31, p = 0.004], but no signiﬁcant
eﬀect of chronic treatment [F(1,8) = 0.62, p > 0.05] and no
hormone status × chronic treatment interaction [F(1,8) = 0.01,
p > 0.05]. In the groups that received their chronic treatments
from early adulthood onward, there were no signiﬁcant eﬀects
in the untrained groups [hormone status: F(1,7) = 0.08,
p > 0.05; chronic treatment: F(1,7) = 1.80, p > 0.05; chronic
treatment × hormone status: F(1,7) = 0.20, p > 0.05], but there
were signiﬁcant main eﬀects of hormone status [F(1,11) = 32.57,
p < 0.001] and chronic treatment [F(1,11) = 10.82, p = 0.007]
in the trained groups; the chronic treatment × hormone status
interaction though was not signiﬁcant [F(1,11) = 0.27, p > 0.05].
Of particular note for BDNF was the fact that OVX signiﬁcantly
increased BDNF in the untrained groups that initiated their
chronic treatment during adolescence, irrespective of the chronic
treatment; however, chronic 9-THCwas able to decrease BDNF
in both the intact and OVX groups if it was initiated during early
adulthood.
Uterine Weights
Uterine weight was analyzed using a three-way ANOVA, with
age (adult versus adolescent), hormone status (intact versus
OVX), and chronic treatment (saline versus 9-THC) serving
as factors. This analysis indicated that there was a signiﬁcant
main eﬀect of hormone condition on uterine weight at sacriﬁce
[F(1,62) = 126.21, p < 0.001], but no main eﬀects for age
[F(1,62) = 0.002, p > 0.05] or chronic treatment [F(1,62) = 0.05,
p > 0.05], and no signiﬁcant interactions among the three
factors [age × hormone status: F(1,62) = 0.01, p > 0.05,
age × chronic treatment: F(1,62) = 0.002, p > 0.05, hormone
status × chronic treatment: F(1,62) = 0.5, p > 0.05, or
age × hormone status × chronic treatment: F(1,62) = 0.57,
p > 0.05]. The mean weight and SEM for the uteri of all of the
gonadally intact females (n = 23) was 48.2 ± 2.8 mg, whereas the
mean weight and SEM for the uteri of the OVX females (n = 24)
was 10.6 ± 1.5 mg, conﬁrming the eﬀectiveness of the hormone
manipulation (i.e., OVX).
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FIGURE 7 | Effects of chronic 9-THC and hormone status on the
endogenous levels of CB1R, AHA1, and HSP90β in the striatum. Above
each bar graph are western blots of protein levels in striatal extracts from the
female rats in each of the four chronically treated groups. Levels of each protein
were corrected for the β-actin levels in the same samples and presented as a
ratio of protein to actin in relative units. Asterisks associated with a bar indicate
significant main effects of hormone status, whereas letters indicate significant
differences among the four treatment groups when there were significant main
effects for chronic 9-THC and hormone status or a significant interaction
between the factors (e.g., “a” is different from “b,” but not different from “a,b,c”).
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FIGURE 8 | Effects of chronic 9-THC and hormone status on the
endogenous levels of BDNF in the hippocampus. Above each bar graph
are western blots of protein levels in hippocampal extracts from the female rats
in each of the four chronically treated groups. Levels of each protein were
corrected for the β-actin levels in the same samples and presented as a ratio of
protein to actin in relative units. Asterisks associated with a bar indicate
significant main effects of hormone status, whereas letters indicate significant
differences among the four treatment groups when there were significant main
effects for both chronic 9-THC and hormone status (e.g., “a” is different from
“b,” but not different from “a,c”).
Discussion
Long-term chronic 9-THC administration initiated during
either adolescence or early adulthood consistently disrupted
the rate and accuracy with which subjects both acquired new
information (sequence acquisition) and emitted well-rehearsed
information (sequence performance). This was indicated bymain
eﬀects of chronic 9-THC administration on both dependent
measures of responding irrespective of hormone status (intact
versus OVX) and the age of initiation. However, the age of
initiation substantially aﬀected the development of tolerance to
its disruptive eﬀects. In subjects that were administered chronic
9-THC from early adulthood onward, substantial tolerance
developed irrespective of hormone status as demonstrated by
an approximately 10-fold shift to the right in the 9-THC
dose-eﬀect curves for response rate in both hormone groups,
and possibly larger shifts for percent errors. In the subjects
that were administered chronic 9-THC from adolescence
onward, the development of tolerance was not as complete, or
as extensive, and the OVX group was more sensitive to the
rate-decreasing and error-increasing eﬀects of 9-THC than the
intact group. All of these eﬀects also occurred in the absence
of dependence, which was assessed by the administration of
the CB1R antagonist rimonabant. Furthermore, CB1R protein
levels in the hippocampus and striatum were not uniformly
aﬀected by chronic 9-THC. In fact, hormone status produced
more signiﬁcant eﬀects on CB1R, AHA1, and HSP90β levels
in hippocampus than chronic 9-THC treatment; in striatum,
the eﬀects varied substantially. Hippocampal BDNF was aﬀected
by hormone status more when chronic 9-THC was initiated
during adolescence than when it was initiated during early
adulthood.
These types of longitudinal studies are rare and extraordinarily
few animals studies have examined the eﬀects of almost life-
long 9-THC, as was the case for the groups that initiated
9-THC during adolescence. In previous studies from this
laboratory, the long-term interactive eﬀects of chronic 9-THC
and ovarian hormones were examined by administering chronic
9-THC to intact and OVX female rats for some period of time
(e.g., 40 days) and then assessing adult sensitivity (Winsauer
et al., 2011a). This assessment generally occurred after drug-
free training and sensitivity was quantiﬁed by comparing the
dose-eﬀect curves for the experimental groups (intact/THC,
OVX/saline, and OVX/THC) with those of the control group
(intact/saline). The age-dependence of these eﬀects was also
demonstrated by moving the period of chronic 9-THC
administration from adolescence to early adulthood (Winsauer
and Sutton, 2014). In contrast, the aim of the present study
was to use the same complex operant procedure as a means of
determining whether the age of initiation and hormonal status
in females aﬀected the development of tolerance to 9-THC.
Thus, chronic 9-THC was initiated during either adolescence
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or early adulthood and continued through behavioral training
and the establishment of the dose-eﬀect curves for 9-THC and
the CB1R antagonist rimonabant. In a very pragmatic way, this
protocol alone provided direct evidence of the disruptive eﬀects
of chronic 9-THC administration on adolescent development,
as comparability between the adolescent groups that received
chronic 9-THC and saline could only be maintained by moving
the chronic 9-THC injections to the afternoons temporarily;
and therefore, the training time only diﬀered from the early
adult groups by an average of less than 10 days (see Table 1).
Interestingly, these observations contrast somewhat with data
reported in the literature suggesting that adolescent rats may be
less sensitive to the behaviorally disruptive eﬀects of 9-THC
than adults (Schramm-Sapyta et al., 2007) and that adolescent
females can show greater desensitization of CB1R than adult
females and males at both ages (Burston et al., 2010). At
least in males, there are also reports that CB1R may be down
regulated more readily in adolescents than adult rats (Dalton
and Zavitsanou, 2010). Also, Schneider et al. (2008) found that
incrementing doses of WIN 55,212-2 over 25 days produced
greater eﬀects on object/social recognition, social behavior, play,
and self-grooming in pubertal male rats than adult male rats.
With respect to the present study, the adolescent groups that
were 9-THC naïve (i.e., chronically administered saline) were
less potently aﬀected by acute 9-THC than the 9-THC naïve
adults.
In many ways, the present results may be summarized best by
Barnes and Fried (1974), who stated that ‘degrees of tolerance
exist and that the age of the subject at the time of the initial
chronic 9-THC experience interacts with the later development
of tolerance to the drug’ (p. 181). Unfortunately, in contrast to
the present results, they found that rats that received 9-THC
as adolescents developed tolerance more quickly than their adult
counterparts. This was determined in their study by rotorod
and balance-beam behavior after 41 days of chronic 9-THC
(4 mg/kg every other day) and a 21-day drug-free period in
male rats that were either 30 or 90 days of ages at the start of
the chronic regimen. Obviously, there are numerous diﬀerences
between the two studies, including the type of behavior, the
duration of chronic 9-THC administration, and the insertion of
a drug-free period, but the main diﬀerence may be the use of male
versus female rats. This is not to say that these other variables are
not important, but that the long-term behavioral eﬀects resulting
from chronic cannabinoids during adolescence are frequently
diﬀerent in males and females (Biscaia et al., 2003; Mateos et al.,
2011; Realini et al., 2011; Lee et al., 2014), and that adolescence,
as opposed to adulthood, is a particularly vulnerable time for
females (O’Shea et al., 2006; Cha et al., 2007; Winsauer et al.,
2011a) and males (Stiglick and Kalant, 1983, 1985; Schneider and
Koch, 2003; Cha et al., 2006).
Along with the unexpected sensitivity of the adolescent
groups, the present data indicated that: (1) the initiation of
chronic 9-THC during early adulthood eliminated diﬀerences
in the development of tolerance between intact and OVX females,
and (2) the sensitivity of the OVX groups was increased relative
to the intact groups if chronic 9-THC administration was
initiated during adolescence. The ﬁrst result was unexpected
because recent data from our laboratory indicated that a period
of chronic administration during early adulthood (PND 75–115)
did not alter the hormonally dependent eﬀects of 9-THC. In
other words, intact female rats were more sensitive than OVX
females to the rate-decreasing and error-increasing eﬀects of 9-
THC regardless of when a 40-days period of chronic 9-THC
was initiated (adolescence or early adulthood). However, in the
present study, there was no main eﬀect of hormone status or
a signiﬁcant interaction between hormone status and chronic
9-THC administration for either dependent measure if it was
initiated during early adulthood. In fact, the dose-eﬀect curves for
both the intact and OVX groups were remarkably similar, as was
the magnitude of the level of tolerance. These data would suggest
that long-term chronic 9-THC can antagonize the eﬀects of
ovarian hormones on acquisition and performance behavior, and
support existing data indicating that the interaction between
the sex hormones and cannabinoids or endocannabinoids is
bidirectional (for reviews, see Lopez, 2010; Viveros et al., 2011;
Gorzalka and Dang, 2012; Craft et al., 2013).
The second long-term eﬀect of uninterrupted chronic 9-
THC from adolescence onward was the relative increase in the
sensitivity of the OVX females compared to intact females. As
mentioned above, we found OVX females to be less sensitive
to 9-THC than intact females in two studies (Winsauer
et al., 2011a; Winsauer and Sutton, 2014), irrespective of the
age at which the 40 days of chronic 9-THC administration
was initiated (i.e., adolescence or early adulthood). The only
diﬀerence between these two studies and the present study was
that both of the prior studies had a substantial drug-free period
after the 40 days of 9-THC, but prior to the acute dose-
eﬀect determinations, for behavioral training. This would suggest
that some of the organizational and activational eﬀects of the
ovarian hormones likely occur during this drug-free period, and
as a result these intact females have an increased sensitivity
to subsequent cannabinoid administration compared with an
OVX female. Conversely, uninterrupted chronic 9-THC from
adolescence onward must prevent some of the organizational
eﬀects of the ovarian hormones. If this is the case, this may
be some of the ﬁrst evidence (to our knowledge) that suggests
that chronic 9-THC may oppose the organizational eﬀects of
the ovarian hormones, as well as their activational eﬀects (Craft
et al., 2013). Exactly which organizational eﬀects is diﬃcult to say,
but clearly the reduced sensitivity of the intact group compared
to the OVX group after chronic administration in adolescents
(particularly at higher doses) is something that could have long-
term behavioral ramiﬁcations.
Although the eﬀects of OVX on the pharmacokinetic
(metabolic) disposition of 9-THC in females was not examined
in this study, there is evidence that male and female
rats metabolize 9-THC diﬀerently via the P450 system.
Females produce more of the active metabolite 11-hydroxy-
9-tetrahydrocannabinol (11-OH-9-THC), whereas males
produce more inactive metabolites (Narimatsu et al., 1991). Thus,
female rats likely have more active metabolites in the brain after
both acute and chronic 9-THC administration (Tseng et al.,
2004; Wiley and Burston, 2014). In one study, for example,
concentrations of 11-OH-9-THC in the brain tissue of females
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peaked at 30 and 120 min and then declined to near zero levels by
4 h, as compared with brain tissue concentrations in males that
reached a lower maximal peak by 30 min and then declined to
near zero levels by 2 h (Tseng et al., 2004). Whether the metabolic
diﬀerences between females and males has some similarity to
diﬀerences between intact and OVX females, due to the loss of
hormone in the OVX females, is not known. Nevertheless, such
a dispositional diﬀerence would not easily explain the increased
sensitivity of OVX females chronically treated with 9-THC
during adolescence.
As in previous animal studies where chronic administration
of 9-THC may have led to dependence (Aceto et al., 1996;
Cook et al., 1998; Delatte et al., 2002), the level of dependence
was assessed by the administration of varying doses of the
CB1R antagonist rimonabant (or SR141716A as it was formerly
known). The major advantage of administering an antagonist
over simply terminating9-THC administration for some period
of time was that a precipitated withdrawal often elicits a larger
number of withdrawal-associated eﬀects, and they generally
occur over a more predictable time frame and with greater
intensity, which makes quantifying these eﬀects easier. Among
some of the many withdrawal-associated eﬀects reported for 9-
THC are: scratching, facial rubs, licking, wet-dog shakes, paw
shakes, retropulsion, head shakes, forepaw treading, and ptosis
(Aceto et al., 1996). In behavioral studies involving operant
procedures, the disruption of food-maintained responding has
also served as a means for assessing dependence on 9-THC.
In fact, disruptions of schedule-controlled responding have been
posited to be a more sensitive indicator of dependence than many
of the aforementioned gross behavioral eﬀects. For example,
both Slifer et al. (1984) and Beardsley et al. (1986) found that
reductions in rates of operant responding during withdrawal
from 9-THC and phencyclidine, respectively, occurred more
reliably than dramatic changes in gross behavior and often took
longer to return to control levels after withdrawal of 9-THC
than gross behavior. In the present study, 0.32–10 mg/kg of
rimonabant disrupted response rate and accuracy with similar
potency in both the saline- and 9-THC-treated groups, and
based on this similarity there was little or no evidence that
signiﬁcant dependence had developed during chronic 9-THC
administration. Both the saline- and 9-THC-treated females
were, however, more sensitive to the eﬀects of rimonabant than
the males from a previous study (Delatte et al., 2002). In that
study, 1 mg/kg did not disrupt either response rate or percent
errors prior to chronic 9-THC administration. These data
support the long-standing supposition that dependence is a dose-
dependent phenomenon (Jones et al., 1976), and that it may, or
may not, be evident with the development of tolerance.
Because OVX occurred at the same time for both the
adolescent and early adult groups, and because there was
no signiﬁcant diﬀerence in tolerance between the intact and
OVX groups from early adulthood, the reduced magnitude of
tolerance in the adolescent groups point to an age-dependent
eﬀect. In other words, even OVX females were able to develop
substantial tolerance if they were allowed to age for some drug-
free period, which suggests the endocannabinoid system (like
the endocrine system) and its interaction with the HPG/HPA
axes (Lopez, 2010) must also be allowed to mature or function
unperturbed to develop properly. Furthermore, at least in
hippocampus, the absence of a main eﬀect of chronic 9-
THC on CB1R suggests that it may well be the downstream
signaling mechanisms that require time for development (e.g.,
Ras/ERK signaling Rubino et al., 2005). This latter suggestion
is supported by the fact that hormone status had completely
opposite eﬀects on the relative expression levels of AHA1 and
HSP90β in the hippocampus when the age of chronic 9-
THC administration diﬀered. We previously demonstrated that
AHA1, a co-activator of HSP90, speciﬁcally upregulates the
traﬃcking and signaling of CB1R (Filipeanu et al., 2011) and
the present data suggest that subtle changes in the levels of
AHA1 could alter CB1R subcellular localization, and thus, the
response to 9-THC administration. Interestingly, the present
hippocampal data also show an inverse relationship between
AHA1 and HSP90β expression that was not seen previously
with cerebellar tissue from adults that received the drug for
40 days as adolescents (Filipeanu et al., 2011). Whether this
relationship is unique to the hippocampus or is the result of
the uninterrupted regimen of chronic 9-THC remains to be
demonstrated, but there is little doubt that expression levels may
be under the control of multiple factors and that uninterrupted
chronic 9-THC from adolescence onward can produce brain-
region-speciﬁc eﬀects that are diﬀerent from those that occur
after a drug-free maturation period.
Unlike the eﬀects of chronic 9-THC and hormone status
on CB1R signaling proteins in hippocampus, the eﬀects of
these variables in striatum varied across ages and the speciﬁc
protein. For instance, despite signiﬁcant tolerance, there was no
CB1R downregulation in either hormone group administered
chronic 9-THC from early adulthood onward and there was
no readily discernable pattern of eﬀects on AHA1 or HSP90β
in the hormone groups from either age of initiation. These data
indicate that the expression, subcellular localization and signaling
of CB1R and its co-chaperones are regulated in a brain-region
speciﬁc manner in response to chronic 9-THC. Classically,
CB tolerance has been tied directly to reversible and regionally
selective downregulation of CB1R in humans (Villares, 2007;
Hirvonen et al., 2012) as well as animals (Oviedo et al., 1993; Fan
et al., 1996; Romero et al., 1998). However, more recent studies
with various cannabinoid agonists have provided evidence that
behavioral tolerance can occur with CB1R desensitization alone
(Rubino et al., 2000a; Daigle et al., 2008), or a region-dependent
balance of desensitization and downregulation (Breivogel et al.,
1999; McKinney et al., 2008). Two data-driven suppositions
that have also been advanced are: (1) desensitization and
downregulation likely have diﬀerent agonist-dependent time
courses (Wu et al., 2008), and (2) desensitization likely occurs
before downregulation (Rubino et al., 2000a). Age-dependent
diﬀerences in expression levels of CB1 mRNA have even been
found within the diﬀerent regions of striatum (Van Waes et al.,
2012), and this region has been shown to adapt more slowly
to chronic CB than hippocampus or cerebellum (Romero et al.,
1998; Zhuang et al., 1998; Breivogel et al., 1999; McKinney et al.,
2008). Finally, in what could explain some of our results from
the present study, Zhuang et al. (1998) suggested that CB1R
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expression (or at least mRNA for CB1R) may be able to return to
control levels after a period of time even if increases in the level
of receptor agonists are sustained. In the striatum in particular,
tolerance to the hypomotility produced by chronic 9-THC was
proposed to depend more on Ras/ERK signaling than either
downregulation or desensitization (Rubino et al., 2005).
As was true for AHA1 and HSP90β expression in
hippocampus, the eﬀects of chronic 9-THC administration on
hippocampal BDNF diﬀered depending on the age of initiation.
BDNF is known as an important signaling molecule that is
aﬀected by chronic cannabinoids in a sex- and age-dependent
manner (Lopez-Gallardo et al., 2012). In the present study,
when chronic 9-THC was initiated during adolescence, it
had little or no eﬀect on adult BDNF expression as it was
signiﬁcantly increased only in the treated and untreated OVX
females. This is consistent with ﬁndings from Riebe et al. (2010),
who also postulated that the upregulation of CB1R densities
occurred in the OVX females because estradiol typically inhibits
CB1R expression. Interestingly, they also postulated that an
upregulation of hippocampal CB1R densities could occur as
a compensatory response to 9-THC’s capacity to produce
desensitization both acutely (Mize and Alper, 2000; Wu et al.,
2008) and chronically (Rubino et al., 2000c; Daigle et al., 2008).
If correct, this mechanism could also help explain why CB1R
densities were increased even in the OVX females that were
chronically administered 9-THC from adolescence onward.
When chronic 9-THC was initiated during early adulthood,
BDNF expression was decreased in both intact and OVX females
compared to controls (see Figure 8), although this was only
a trend for the untrained females. Nevertheless, these data
are also consistent with the existing literature because they
show the capacity of chronic 9-THC to decrease BDNF in
hippocampus (e.g., Derkinderen et al., 2003), an area integrally
involved in learning and memory (Lichtman et al., 1995; Wise
et al., 2009; Abush and Akirav, 2010). This would also seem
to be an eﬀect that is readily opposed by estradiol in the
hippocampus (Scharfman and Maclusky, 2005; Wallace et al.,
2006). For some time, there was evidence that chronic 9-THC
altered hippocampal morphology in ‘young adult’ male rats (e.g.,
Landﬁeld et al., 1988; Lawston et al., 2000), but scientists had
not worked out all of the biochemical pathways that can lead
to neuro- and synaptogenesis, and there was a true lack of
data regarding these processes in females. Moreover, researchers
are only now beginning to understand all of the complexities
involved in neural and synaptic plasticity in the hippocampus,
and the profound role estrogens have on the structure and
function of the hippocampus during pubertal development (Sisk
and Zehr, 2005) and throughout females’ lives (Adams et al.,
2001; also see Spencer et al., 2008, for a review). Some of the
more recent studies have also established a clear brain-region-
dependent interaction between BDNF and CB1R (Butovsky et al.,
2005; De Chiara et al., 2010). For example, chronic prenatal
administration of WIN 55,212,2 has been shown to produce
signiﬁcant reductions in BDNF protein levels in cytoplasmic
fractions from hippocampus and frontal cortex of adult rats
(Maj et al., 2007), but chronic 9-THC for 7 days produced
a clear up-regulation of BDNF mRNA and protein in nucleus
accumbens, ventral tegmental area, and mPFC (Butovsky et al.,
2005). Unfortunately, these studies also show the extent to
which chronic 9-THC, hormone status, brain region, and age
can interact to aﬀect neural and synaptic plasticity, and that
substantial research will be needed to fully understand their
interaction as it relates to acquisition and performance behavior.
In summary, the present data suggest that the capacity of
females to become tolerant to the disruptive eﬀects of chronic
9-THC on acquisition and performance behavior can diﬀer
markedly depending on the presence of ovarian hormones and
the age of initiation in females. This was evident from the data
indicating that: (1) tolerance developed to a much lesser extent
when chronic 9-THC was initiated in adolescence versus early
adulthood, and (2) adolescent initiation of chronic 9-THC
markedly reduced the sensitivity of intact females and increased
the sensitivity of OVX females – an eﬀect that did not occur
when chronic 9-THC was initiated in early adulthood (e.g.,
Winsauer and Sutton, 2014) or when a drug-free period followed
40 days of chronic 9-THC during adolescence (Winsauer et al.,
2011a). Together, these data suggest that a drug-free period
may be necessary for both the endocrine and endocannabinoid
systems to develop properly and exert their usual inﬂuence on
behavior. The age- and region-dependence of the interaction
between hormone status and chronic 9-THC was also evident
from the expression of CB1R, AHA1, and HSP90β. In the
hippocampus of females, chronic 9-THC could not obscure
the predominant eﬀect of hormone status on CB1R expression
regardless of the age of initiation; however, age of initiation
resulted in contrasting levels of adult expression of AHA1 and
HSP90β. In striatum, chronic 9-THC could not obscure the
inﬂuence of hormone on adult CB1R expression if it was initiated
during adolescence, and had no long-term eﬀect on CB1R if
it was initiated during early adulthood. The eﬀects on AHA1
and HSP90β in striatum were mixed. Finally, the eﬀects of
chronic 9-THC on adult hippocampal BDNF were obscured
by hormone status if administration began during adolescence,
but BDNF was decreased by it if administration began in early
adulthood. Taken together, these data indicate that chronic
9-THC from adolescence onward limits the development of
behavioral tolerance compared with chronic9-THC later in life,
andmay reduce the long-term responsiveness of the CB system in
various brain regions critical for learning and memory.
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